Weimand BM, Solli KK, Reichelt WH, Tanum L. Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: a Norwegian longitudinal recovery trial (NaltRec study). Contemp Clin Trials Commun. 2021;21: 100728.
Tanum L, Solli KK, Latif ZE, Benth JS, Opheim A, Sharma-Haase K, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiat. 2017;74(12):1197–205.
Solli KK, Latif ZE, Opheim A, Krajci P, Sharma-Haase K, Benth JS, et al. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. Addiction. 2018;113(10):1840–9.
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.
Leshner AI. Addiction is a brain disease, and it matters. Science. 1997;278(5335):45–7.
McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689–95.
EMCDDA. European Drug Report: Trend and Developments. 2020. https://www.emcdda.europa.eu/publications/edr/trendsdevelopments/2020_en.
United Nations Office on Drugs and Crime, World Drug Report 2021 (United Nations publication, Sales No. E.21.XI.8).
Jarvis BP, Holtyn AF, Subramaniam S, Tompkins DA, Oga EA, Bigelow GE, et al. Extended-release injectable naltrexone for opioid use disorder: a systematic review. Addiction. 2018;113(7):1188–209.
Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–6.
Kober H. Emotion regulation in substance use disorders. Handbook of emotion regulation. 2nd ed. New York: The Guilford Press; 2014. p. 428–46.
Laudet AB. What does recovery mean to you? Lessons from the recovery experience for research and practice. J Subst Abuse Treat. 2007;33(3):243–56.
Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-41, HHS Publication No. (SMA) 11–4658. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2011.
Dennis ML, Foss MA, Scott CK. An eight-year perspective on the relationship between the duration of abstinence and other aspects of recovery. Eval Rev. 2007;31(6):585–612.
Hser YI. Predicting long-term stable recovery from heroin addiction: findings from a 33-year follow-up study. J Addict Dis. 2007;26(1):51–60.
Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psych. 2015;23(2):76–89.
World Health Organization (WHO). Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009.
Simoens S, Matheson C, Bond C, Inkster K, Ludbrook A. The effectiveness of community maintenance with methadone or buprenorphine for treating opiate dependence. Br J Gen Pract. 2005;55(511):139.
Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies–tackling the opioid-overdose epidemic. N Engl J Med. 2014;370(22):2063–6.
Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622-e.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD002207 (pub4).
Zinöcker S, Shrestha M, Næss GE, Kornør H. Effekter av legemiddelassistert rehabilitering sammenliknet med ikke-medikamentell behandling av opioidavhengighet: En systematisk oversikt [Effects of opioid maintenance treatment versus no drug therapies for opioid dependence: A systematic review] Rapport−2020. Oslo: Folkehelseinstituttet, 2020.
Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207–25.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):Cd002209.
Carlsen SL, Lunde LH, Torsheim T. Opioid and polydrug use among patients in opioid maintenance treatment. Subst Abuse Rehabil. 2020;11:9–18.
Soyka M, Strehle J, Rehm J, Bühringer G, Wittchen HU. Six-year outcome of opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res. 2017;23(2):97–105.
White WL, Campbell MD, Spencer RD, Hoffman HA, Crissman B, DuPont RL. Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention. J Psychoact Drugs. 2014;46(2):114–22.
Witte TH, Jaiswal J, Mumba MN, Mugoya GCT. Stigma surrounding the use of medically assisted treatment for opioid use disorder. Subst Use Misuse. 2021;56(10):1467–75.
Steiro A, Hestevik CH, Shrestha M, Muller AE. Erfaringer blant pasienter og helseperso nell med legemiddelassistert rehabilitering (LAR): En systematisk oversikt over kvalitative studier. [Patients’ and healthcare personnel’s experiences with opioid maintenance treatment (OMT): A systematic review of qualitative studies] Rapport − 2020. Oslo: Folkehelseinstituttet, 2020.
Grønnestad TE, Sagvaag H. Stuck in limbo: illicit drug users’ experiences with opioid maintenance treatment and the relation to recovery. Int J Qual Stud Health Well Being. 2016;11(1):31992.
Granerud A, Toft H. Opioid dependency rehabilitation with the opioid maintenance treatment programme—a qualitative study from the clients’ perspective. Subst Abus Treat Prev Policy. 2015. https://doi.org/10.1186/s13011-015-0031-4.
Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs. 2012;72(2):217–28.
McKeganey N, Bloor M, Robertson M, Neale J, MacDougall J. Abstinence and drug abuse treatment: results from the Drug Outcome Research in Scotland study. Drugs Educ Prev Policy. 2006;13(6):537–50.
McKeganey N, Morris Z, Neale J, Robertson M. What are drug users looking for when they contact drug services: abstinence or harm reduction? Drugs: education. Prev Policy. 2004;11(5):423–35.
Zaaijer ER, Goudriaan AE, Koeter MWJ, Booij J, van den Brink W. Acceptability of extended-release naltrexone by heroin-dependent patients and addiction treatment providers in the Netherlands. Subst Use Misuse. 2016;51(14):1905–11.
Bigelow GE, Preston KL, Schmittner J, Dong Q, Gastfriend DR. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose-effects and time-course. Drug Alcohol Depend. 2012;123(1–3):57–65.
Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology. 2006;189(1):37–46.
Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psych. 2006;63(2):210–8.
Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA Jr, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–42.
Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628–37.
Kunøe N, Lobmaier P, Ngo H, Hulse G. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction. Br J Clin Pharmacol. 2014;77(2):264–71.
Latif ZE, Saltyte Benth J, Solli KK, Opheim A, Kunoe N, Krajci P, et al. Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study. JAMA Psychiatry. 2018. https://doi.org/10.1001/jamapsychiatry.2018.3537.
Latif ZE, Solli KK, Opheim A, Kunoe N, Benth JS, Krajci P, et al. No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: a 3-month randomized study and 9-month open-treatment follow-up study. Am J Addict. 2019;28(2):77–85.
Solli KK, Opheim A, Latif ZE, Krajci P, Benth JS, Kunoe N, et al. Adapting treatment length to opioid-dependent individuals’ needs and preferences: a 2-year follow-up to a 1-year study of extended-release naltrexone. Addiction. 2020. https://doi.org/10.1111/add.15378.
Alkermes. Vivitrol [Internet]. 2021. https://www.alkermes.com/products/vivitrol. Accessed 12 July 2021.
DeFulio A, Everly JJ, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, et al. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend. 2012;120(1–3):48–54.
Marcus R, Bojko MJ, Mazhnaya A, Makarenko I, Filippovych S, Dvoriak S, et al. A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine. J Subst Abuse Treat. 2018;86:86–93.
Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, et al. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addit Sci & Clin Pract. 2019;14(1):37.
Gauthier P, Greco P, Meyers-Ohki S, Desai A, Rotrosen J. Patients’ perspectives on initiating treatment with extended-release naltrexone (XR-NTX). J Subst Abuse Treat. 2021;122: 108183.
Hoffman KA, Baker R, Fanucchi LC, Lum PJ, Kunkel LE, Ponce Terashima J, et al. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. Addict Sci Clin Pract. 2021;16(1):67.
Brenna IH, Marciuch A, Birkeland B, Veseth M, Røstad B, Løberg E-M, et al. Not at all what I had expected discontinuing treatment with extended-release naltrexone (XR-NTX) a qualitative study. J Subst Abuse Treat. 2021. https://doi.org/10.1016/j.jsat.2021.108667.
Elo S, Kyngas H. The qualitative content analysis process. J Adv Nurs. 2008;62(1):107–15.
Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004;24(2):105–12.
Lobmaier PSI, Lillevold P, Waal H, Bussesund K, Clausen T. Statusrapport. LAR behandling under første åretmed Covid-19 pandemi. [The yearly national OMT status report 2020. OMT treatment during the first year of the Covid-19 pandemic]. Oslo, SERAF. 2020.
Steingrímsson S, Carlsen HK, Sigfússon S, Magnússon A. The changing gender gap in substance use disorder: a total population-based study of psychiatric in-patients. Addiction. 2012;107(11):1957–62.
Seedat S, Scott KM, Angermeyer MC, Berglund P, Bromet EJ, Brugha TS, et al. Cross-national associations between gender and mental disorders in the world health organization world mental health surveys. Arch Gen Psych. 2009;66(7):785–95.
NVivo (Version 12). 2018. https://www.qsrinternational.com/nvivo-qualitative-data-analysis-software/home: QSR International Pty Ltd. Accessed 31 May 2021
Faulkner SL, Trotter SP. Theoretical Saturation. In: Jörg M, Christine SD, Robert FP, editors. The International Encyclopedia of Communication Research Methods. Hoboken: Wiley; 2017.
Skewes MC, Gonzalez VM. The Biopsychosocial Model of Addiction. In: Miller PM, editor. principles of addiction. San Diego: Academic Press; 2013. p. 61–70.
Everly JJ, DeFulio A, Koffarnus MN, Leoutsakos JM, Donlin WD, Aklin WM, et al. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction. 2011;106(7):1309–18.
Jarvis BP, DeFulio A, Long L, Holtyn AF, Umbricht A, Fingerhood M, et al. Factors associated with using opiates while under extended-release naltrexone blockade: a descriptive pilot study. J Subst Abuse Treat. 2018;85:56–60.
Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Gossop M, Hegstad S, et al. Challenges to antagonist blockade during sustained-release naltrexone treatment. Addiction. 2010;105(9):1633–9.
Hassan AN, Le Foll B. Polydrug use disorders in individuals with opioid use disorder. Drug Alcohol Depend. 2019;198:28–33.
Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78–82.
Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303–10.
Heikman PK, Muhonen LH, Ojanperä IA. Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine. BMC Psych. 2017;17(1):245.
Soyka M, Zingg C, Koller G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008;11(5):641–53.
Lewis M. Addiction and the brain: development, not disease. Neuroethics. 2017;10(1):7–18.
Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psych. 2004;61(8):807–16.
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse results from the epidemiologic catchment area (ECA) study. JAMA. 1990;264(19):2511–8.
Rounsaville BJ, Weissman MM, Crits-Christoph K, Wilber C, Kleber H. Diagnosis and symptoms of depression in opiate addicts course and relationship to treatment outcome. Arch Gen Psych. 1982;39(2):151–6.
Ravndal E, Lauritzen G. Rusmisbruk, angst og depresjon etter 10 år: En prospektiv undersøkelse av stoffmisbrukere med og uten LAR-behandling. Nordic Stud Alcohol Drugs. 2015;32(5):495–508.
American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. J Addict Med. 2020;14(2S):1–91.
Leamy M, Bird V, Le Boutillier C, Williams J, Slade M. Conceptual framework for personal recovery in mental health: systematic review and narrative synthesis. Br J Psych. 2011;199(6):445–52.
Laudet AB, Morgen K, White WL. The role of social supports, spirituality, religiousness, life meaning and affiliation with 12-step fellowships in quality of life satisfaction among individuals in recovery from alcohol and drug problems. Alcohol Treat Q. 2006;24(1–2):33–73.
White W, Kurtz E. the varieties of recovery experience: a primer for addiction treatment professionals and recovery advocates. Int J Self Help Self Care. 2005;3:21–61.
Laudet AB, White WL. Recovery capital as prospective predictor of sustained recovery, life satisfaction, and stress among former poly-substance users. Subst Use Misuse. 2008;43(1):27–54.
Neale J, Nettleton S, Pickering L. What is the role of harm reduction when drug users say they want abstinence? Int J Drug Policy. 2011;22(3):189–93.